Houston Methodist Research Institute,
Summary:Wait, not as in â€œpost-mortemâ€â€¦. Rather as in â€œpost-genomicsâ€â€¦. As in: â€œLetâ€™s use the knowledge gained in these last 20 years or so of research and development in nanomedicine and build the next generation of advances, where neededâ€. This is the focus of the talk, with an obvious bias toward the lines of investigation and clinical translation that we have been engaging in â€“ simply because though they are probably not the smartest things around, these are still the ones we know best! So I will talk about a 25-year progression ( = string of failures, mostly) from photolithography-based silicon particles with drug reservoirs (1992) and the beginning of nanofluidics (1994ish) to multi-stage injectable drug delivery systems coupling micro- and nano-platforms (2008) with nanoporous silicon; transport oncophysics (2011) with its applications to immunotherapy (2015), to end with a new beginning: injectable nano-particle generators (iNPG), which in combination with polymeric doxorubicin (pDox) are actually able to completely cure metastatic forms of triple negative breast cancer in about 40% of the cases in preclinical models. It was time, no? Next challenge â€“ move to clinic. Coming up.